Biochemicals and Reagents

<p>Inhibitor of EGFR, HER2 and VEGFR2 tyrosine kinases</p>

<p>NVP-BVU972 is a small molecule inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor. It has been shown to inhibit the growth of cancer cells in vitro and in vivo. NVP-BVU972 binds to the ATP binding site of the kinase domain and inhibits protein synthesis by preventing phosphorylation of downstream substrates. This drug also has a pharmacokinetic profile that is not affected by renal or hepatic dysfunction. NVP-BVU972 is currently being evaluated as a predictive biomarker for cancer treatment response.</p>

<p>Myxochelin A is an iron-chelating siderophore, which is a specialized secondary metabolite produced by certain strains of myxobacteria. These microorganisms, often found in soil and decomposing material, synthesize Myxochelin A to scavenge iron from the environment, essential for their survival and growth. The mode of action of Myxochelin A involves the sequestration of ferric iron (Fe^3+) ions through its high-affinity binding sites. This effectively deprives competing microorganisms of the iron required for crucial biological processes, imparting an antimicrobial effect.</p>

<p>Prezatide is a peptide that is used as a research tool. It is an activator of ion channels and has been shown to inhibit the activation of these channels by other ligands. Prezatide binds to the receptor and blocks the binding of ligands, which prevents their activation of ion channels. Prezatide copper acetate is purified to high purity and free from contaminants such as endotoxins, pyrogens, or other impurities.</p>

<p>MK-2461 is an orally bioavailable small molecule that binds to the epidermal growth factor receptor (EGFR) and inhibits its downstream signaling. It has been shown to have potent antitumor activity in cell culture and in vivo against a range of tumor types. MK-2461 binds to the EGFR with high affinity, inhibiting the downstream signaling pathway by blocking the activation of molecules such as Raf, MEK1/2, and ERK1/2. The binding site of MK-2461 is located on the extracellular domain of EGFR.</p>

<p>Eptazocine is a peptide that belongs to the group of activators. It is used as a research tool in cell biology, pharmacology, and other life science fields. Eptazocine has been shown to inhibit the activity of ion channels and receptors. Furthermore, it has been used as an antibody to study protein interactions. Eptazocine can be used as a reagent for studying ligand-receptor interactions and is a member of the opioid receptor family. It binds to alpha-subunits of opioid receptors, which are G protein-coupled receptors that activate phospholipase C and inhibit adenylyl cyclase.</p>

<p>BTTAA is water-soluble accelerating ligand for CuAAC that provides much greater rate enhancement compared to previous generation ligands (e.g. THPTA or TBTA).</p>

<p>Utibapril inhibits the activity of angiotensin-converting enzyme (ACE), an enzyme that breaks down the hormone angiotensin I. This leads to an increase in the levels of angiotensin II, which causes blood vessels to narrow by activating a G protein and stimulating the release of a second messenger, nitric oxide. Utibapril is used as a treatment for hypertension, congestive heart failure, and other cardiovascular disorders. It has been shown to cause insulin resistance in patients with type 2 diabetes mellitus and metabolic syndrome. The long-term use of utibapril may lead to congestive heart failure due to its effect on lipid metabolism.</p>

<p>SB 706504 is a small molecule that binds to albumin and inhibits the tyrosine kinase activity of the receptor. It has been shown to inhibit metastasis in cells, as well as cancer cell growth and survival. SB 706504 has also been shown to reduce serum albumin levels, which may be due to its ability to induce apoptosis in cancer cells. This drug has anti-cancer properties, but is not active against acute lymphoblastic leukemia.</p>

<p>Please enquire for more information about Tianeptine-d12 including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>Selonsertib is a highly selective inhibitor of the ATP-binding cassette transporter (ABCA1) that belongs to the class of glp-1 analogues. It is used in combination with other drugs for the treatment of bowel disease, autoimmune diseases, and skin cancer. Selonsertib has been shown to be active against a number of cell types and is also effective in models of metabolic disorders such as hepatic steatosis and kidney fibrosis. Selonsertib blocks ABCA1 by binding to its ATP-binding site, inhibiting cholesterol efflux from cells. This drug may work by restoring mitochondrial membrane potential, which may help prevent or reverse cellular damage caused by oxidative stress.</p>

<p>(R)-Cetirizine-d4 dihydrochloride is an analog of the antihistamine drug cetirizine that has been shown to have potential anticancer properties. It has been found to induce apoptosis in cancer cells and inhibit the activity of kinases, which are enzymes that play a critical role in cell signaling pathways. (R)-Cetirizine-d4 dihydrochloride has been tested against a variety of cancer types, including Chinese hamster ovary and human tumor cell lines. This drug also inhibits amphetamine-induced hyperactivity in mice, suggesting a potential use in treating addiction. Additionally, (R)-Cetirizine-d4 dihydrochloride is excreted primarily through urine and may be used as a kinase inhibitor for research purposes.</p>

<p>Dopropidil is a pharmaceutical preparation that is a fatty alcohol. It is used as an implanting agent and in the production of pharmaceutical dosage forms. Dopropidil has been shown to be effective in experimental models of inflammation, but it has not been studied in humans.</p>

<p>AQ-13 is a quinoline derivative that inhibits the production of inflammatory cytokines and chemokines. AQ-13 is an inhibitor of the enzyme cyclooxygenase-2 (COX-2) that is involved in the production of prostaglandins, which are proinflammatory molecules. The drug has been shown to have anti-inflammatory potency in vitro against LPS-stimulated RAW264.7 cells as well as macrophage-like cells derived from humans. In vivo, AQ-13 was shown to be effective in reducing inflammation caused by infection with the bacterial agent Pullorum or Erysipelothrix rhusiopathiae. This drug has also been shown to inhibit COX-2 activity in humans. Structural analogs of this drug include celecoxib and rofecoxib, which are used for pain relief and prevention of arthritis respectively.</p>

<p>Elenbecestat is a monoclonal antibody that inhibits the enzyme acetylcholinesterase (AChE), which degrades the neurotransmitter acetylcholine. Elenbecestat has been shown to be effective in reducing insulin resistance and improving glucose tolerance in mice. Clinical trials have shown that elenbecestat is safe for use in humans, with few side effects. Elenbecestat has also been shown to reduce fatty acids and protofibril formation in vitro. It also acts as an esterase inhibitor, preventing the hydrolysis of phospholipids. This drug may cause allergic reactions.</p>

<p>TC-MCH 7c is a peptide that inhibits the interaction of proteins. It has been shown to have an affinity for the receptor, and is a ligand for the protein. TC-MCH 7c has been used as a research tool in cell biology and pharmacology, and can be used as an inhibitor or activator for ion channels. TC-MCH 7c has high purity and is suitable for use in life science research.</p>

<p>2-[1-[(2-Amino-7H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)quinazolin-4-one is a synthetic pharmaceutical compound, classified as a small molecule inhibitor. It is derived from a combination of purine and quinazoline structures, typically synthesized through multi-step organic processes. This compound exhibits its mode of action by specifically targeting and inhibiting certain key enzymes or receptors within cellular pathways, potentially interfering with aberrant signaling processes. Through this mechanism, it can modulate biological activity, offering a pathway to correct dysregulated cellular environments.</p>

<p>RGB-286638 is a non-competitive inhibitor of the enzyme DNA topoisomerase II. It has minimal toxicity and a low potential for drug resistance. This agent has been shown to have potent antitumor activity in mice with cancer, inhibit cell growth in cultured cells, and cause necrotic cell death. RGB-286638 binds to the MCL-1 protein and inhibits the production of cytokines that are important for regulating immune responses, such as tumor necrosis factor (TNF). This agent also has a high affinity for actin filaments, which may be due to its ability to bind to myosin heavy chains.</p>

<p>2-(9-((4-Chlorophenyl)thio)-6-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid (BETI) is a synthetic compound that has been shown to have an inhibitory effect on the inflammatory response. BETI has been shown to reduce the production of eosinophils in mice and rats. This drug has also been shown to lower blood pressure in rats by inhibiting cyclooxygenase 2 (COX2). In addition, BETI inhibits Ca2+ responses in human platelets.</p>

<p>Please enquire for more information about Beta-amino-3-methoxy-4-(phenylmethoxy)benzeneethanol including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>Inhibitor of glucose transporter GLUT1; pro-apoptotic</p>

<p>TTA-A2 is a t-type calcium channel blocker. It has been shown to reduce locomotor activity and activate lymphatic vessels in rats. TTA-A2 is also a potential drug target for metabolic disorders, such as obesity, diabetes, and hypertension. TTA-A2 has been shown to have anti-inflammatory effects on the bowel that may be due to its ability to inhibit intracellular calcium concentration. Other studies have shown that TTA-A2 can be used for the treatment of bowel disease and inflammatory bowel disease. In addition, there are no side effect profiles associated with TTA-A2.</p>

<p>RVT 501 is a biochemical reagent, which is derived from synthetic organic compounds with high specificity. Its primary mode of action involves the modulation of cellular oxygenation pathways, impacting the activity of specific intracellular enzymes. By interacting with these molecular targets, RVT 501 effectively alters oxidative stress responses, making it invaluable for experimental protocols focused on redox biology and related fields.</p>

<p>1-[6-Fluoro-3-(4-methylsulfonylpiperazine-1-carbonyl)quinolin-4-yl]-4-phenylpiperidine-4-carbonitrile is a peptide that has been used as a research tool to study protein interactions, antibody and cell biology. It can act as an inhibitor of ion channels such as sodium channels. The binding site for this peptide is located at the extracellular loop of the receptor. 1-[6-Fluoro-3-(4-methylsulfonylpiperazine-1-carbonyl)quinolin-4-yl]-4-phenylpiperidine 4 carbonitrile is a ligand that binds to receptors on cells, which may be responsible for its pharmacological effects.</p>

<p>Neomenthoglycol is a potent anticancer agent that has been shown to induce apoptosis in cancer cells. It is an analog of ghrelin, a hormone that regulates appetite and energy balance. Neomenthoglycol inhibits the activity of kinases, which are enzymes that play a key role in cell signaling pathways. This inhibition leads to the suppression of tumor growth and proliferation. Additionally, neomenthoglycol has been found to be effective against various types of cancer, including breast, colon, and lung cancers. Studies have also shown that neomenthoglycol can inhibit the growth of cancer cells by blocking the action of cellulose synthase inhibitors. Furthermore, neomenthoglycol has demonstrated significant activity against human bladder cancer cells in Chinese hamster ovary (CHO) cells. Its protein kinase inhibitor properties make it a promising candidate for future development as an anticancer therapy.</p>

<p>Please enquire for more information about Acyclovir N-methyl-L-valinate hydrochloride including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>Dehydroaltenusin is a natural product that has been shown to inhibit the growth of cancer cells. It inhibits the suzuki coupling reaction, which is an enzyme that catalyzes the formation of a carbon-carbon bond between two adjacent carbons in a molecule. Dehydroaltenusin may also have anti-HIV effects. The molecular modeling and structural analysis on this compound have shown that it binds to dna as a template for biological function. This compound has been shown to have anti-cancer effects against cervical cancer cells and may be used as an anti-cancer treatment in the future.</p>

<p>5α-7,24-Cholestadiene-d6 is a peptide that can be used as an activator. It is also an inhibitor of ion channels and may be used to study the effects of ligands on the activation of protein interactions. This product is highly pure and has been shown to inhibit cell division in cancer cells. 5α-7,24-Cholestadiene-d6 can be used as a research tool for studying pharmacology, physiology, and biochemistry.</p>

<p>Pt-TTPY is a telomerase inhibitor that binds to the protein subunit of telomerase and prevents the elongation of telomeres. Pt-TTPY has been shown to inhibit cancer cells in vitro, which may be due to its ability to inhibit the synthesis of DNA. The compound also inhibits the proliferation of cancer cells and tumor growth in vivo. Pt-TTPY has been tested in clinical trials for use with cisplatin as a cancer therapy. Pt-TTPY binds to DNA in a sequence-dependent manner and is concomitantly detected by mass spectrometry and fluorescence resonance energy transfer (FRET) measurements. This compound can be used for the detection of telomerase activity or for the measurement of telomere length.</p>

<p>MK-4256 is a synthetic β-carboline alkaloid that binds to the dopamine D2 receptor. It has an imidazole ring and a carboxylic acid. The binding of MK-4256 to the D2 receptor induces an increase in intracellular calcium levels, which leads to an inhibition of various enzymes and protein kinases, such as diastereomer and glipizide. In vitro assays have shown that MK-4256 inhibits the release of insulin from pancreatic cells without affecting other types of cells. This drug has also been shown to be effective in reducing food intake in animals; however, further studies are needed for its clinical use in humans.<br>MK-4256 has been observed to have neuroprotective effects on dopaminergic neurons, as well as anti-inflammatory and analgesic effects in animal models.</p>

<p>The compound 3,3-Difluoro-4-(4-methoxyphenyl)-1-phenylazetidin-2-one is a potent and selective g protein receptor antagonist. It binds to the G protein alpha subunit and blocks the binding of ATP to the alpha subunit, preventing the activation of adenylate cyclase. This compound has shown high efficacy in calcium mobilization assays and can be used as a tool for screening for other ligands that bind to this receptor.</p>

<p>GR 73632 is a neurokinin-1 receptor antagonist that has been shown to have an inhibitory effect on neurokinin-1 receptors. The binding of GR 73632 to the neurokinin-1 receptor leads to the inhibition of pressor responses and inflammatory diseases. It has also shown promise in treating cancer, as well as cervical cancer. GR 73632 binds to the wild-type mouse camp levels and inhibits the release of pressor peptides. This compound also acts as a selective agonist at the caudate putamen, which is involved in controlling blood pressure and urinary bladder function.</p>

<p>G150 is a novel compound that belongs to the group of hydroxylated polyphenols. G150 has been found to be a potent inhibitor of the enzyme tyrosinase and other enzymes involved in melanin synthesis. G150 also has anti-inflammatory properties, inhibiting prostaglandins and leukotrienes, which are inflammatory mediators. G150 inhibits prostate cancer cells by targeting epidermal growth factor receptors. The molecule has shown potential as an agent for the treatment of metabolic disorders and autoimmune diseases.</p>

<p>ASP3026 is a selective tyrosine kinase inhibitor, which is a synthetic small molecule derived from advanced pharmaceutical research. Its mode of action involves the selective inhibition of the anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase implicated in a variety of cancers. By blocking the activity of ALK, ASP3026 interferes with critical signaling pathways that are essential for cancer cell proliferation and survival.</p>

<p>In order to to penetrate human cells, the SARS-CoV-2 coronavirus needs to dock with the host cell surface via one of its surface proteins, the so-called spike protein. This trimeric protein binds to the ACE2 receptor of human cells and enters the cell through the cell membrane. The spike glycoprotein is therefore considered to be a key target for urgently needed vaccines, antibodies and diagnostics.</p>

<p>Hydrogen 4-[(carboxylatomethyl)(methyl)amino]-2,2,2,2-tetrakis(hydroxymethyl)-1λ³-thia-3λ³-thia-2-manganacyclobut-3-en-2-ylium is a peptide that inhibits the activity of ion channels. It has been shown to inhibit the activity of voltage gated sodium channels (VGSCs), potassium channels (Kv1.4), and calcium channels (CaV1.3). This peptide can be used as a research tool for cell biology and pharmacology studies. The purity of this peptide is &gt;99%.</p>

<p>EtDO-P4 is a glucosylceramide synthase inhibitor which reduces the cellular levels of glucosylceramide (Glc-Cer) and the common biosynthetic precursor of most glycosphingolipids (GSLs). EtDO-P4 binds to the Glc-Cer synthase in a competitive manner and prevents the transfer of the first glucosyl residue, thus preventing further biosynthetic diversification into more elaborate glycosphingolipds. EtDO-P4 is a ceramide-like compound that was initially developed as a potential therapeutic for the treatment of diseases associated with altered glycosphingolipid levels. EtDO-P4 has also been used to indirectly increase sialylation levels in erythropoietin production. EtDO-P4 has been suggested, as part of compositions, for treatment of cardiac hypertrophy (Kwak, 2017).</p>

<p>Please enquire for more information about N-Deshydroxy ciclopirox-d11 including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>MC180295 is a bromodomain inhibitor that binds to the CDK4/6-associated bromodomain and inhibits its activity. MC180295 has synergistic effects with venetoclax, which is an inhibitor of Bcl-2. This drug has been shown to be effective against cancer cells in vitro and in vivo, and also sensitizes cancer cells to other drugs. MC180295 is a molecule that suppresses the expression of suppressor genes. It has been shown to be effective at doses of 10 μM or higher in both cell culture and experimental animals.</p>

<p>SB 699551 Dihydrochloride is a selective 5-HT2 receptor antagonist that has been shown to be effective in the treatment of depression and pain. In animal studies, SB 699551 Dihydrochloride has been shown to reduce depression-like behaviors and pain responses. The drug also exhibits high affinity for 5-HT7 receptors with low efficacy. SB 699551 Dihydrochloride is not active against 5-HT1A or 5-HT7 receptors, which are involved in the regulation of serotonin release. This drug may be helpful in the treatment of depression and pain by blocking serotonergic activity at the 5-HT2 receptor.</p>

<p>Stimulates somatotropin release</p>

<p>Tetanus toxin<br>TetTox-B (830-843) DRB1*07:01 is a short part of the tetanus toxin. Tetanus toxin is produced by Clostridium tetani and is a potent neurotoxin. Indeed, tetanus toxin arrives on bloodstream and moves to a receptor complex at the neuromuscular junction.<br>TetTox-B (830-843) DRB1*07:01<br>TetTox-B (830-843) DRB1*07:01 is used to stimulate the immune response and to generate DRB1*07:01-restricted T cells specific for the tetanus toxin peptide. TetTox-B (830-843) is also a classical peptide reference for the binding affinity with DRB1*07:01 molecules.</p>

<p>Lamotrigine N-acetate is a peptide that functions as an activator of ion channels. It is a research tool for the study of ion channels, and it can be used to study the structure of proteins. Lamotrigine N-acetate binds to the receptor site on cells, which stimulates the production of ligands that bind to other receptors. This process may lead to changes in gene expression and protein interactions. It also inhibits some voltage-activated sodium channels, which may lead to changes in neuronal excitability.</p>

<p>4,9-Anhydrotetrodotoxin is a sodium citrate salt of 4,9-dihydro-4,9-dihydroxytetrodotoxin (anhydrotetrodotoxin). It has been shown to bind to the nicotinic acetylcholine receptor on leukemic cells. The hydroxyl group of the cyclohexane ring interacts with the serine hydroxyl group of the receptor and stabilizes the binding. This toxin inhibits calcium ion influx into cells by blocking voltage-gated calcium channels. Chronic oral administration of this drug has been shown to induce clinical responses in patients with chronic myelogenous leukemia who have not responded to other treatments. Hydrophilic interaction chromatography (HILIC) was used to purify 4,9-anhydrotetrodotoxin from a crude extract and monoclonal antibodies were developed for use in immunoassays.</p>

<p>SB-415286 is a small molecule inhibitor of GSK-3β. It prevents phosphorylation of the substrate by GSK-3β, thereby preventing the inhibition of downstream signaling pathways, such as those that regulate energy metabolism and neuronal death. SB-415286 has been shown to inhibit 3t3-l1 preadipocytes differentiation into adipocytes, although it does not inhibit proliferation or stimulate apoptosis. This agent also inhibits neuronal death in axons and axon regeneration in t-cell lymphomas, suggesting that this drug may be useful for treating diseases like Alzheimer's disease or stroke.</p>

<p>(±)-ADX 71743 is a metabotropic glutamate receptor (mGluR) allosteric modulator that increases the activity of the receptor by binding to it. This modulates neurotransmission and reduces pain signals in the central nervous system. (±)-ADX 71743 has been shown to be effective in animal models of nerve injury, sciatic nerve injury, and neuropathic pain. In these models, (±)-ADX 71743 was found to reduce both spontaneous pain and evoked pain responses. It also reduced neuronal hyperexcitability in the dorsal horn of the spinal cord, which is involved in processing nociceptive signals from peripheral tissues. The drug binds to mGluR7 with high affinity, but does not bind to mGluR1 or other subtypes of mGluRs.</p>

<p>ID 8-d3 is a plant growth stimulant, which is derived from lignin, a complex organic polymer found in the cell walls of many plants and algae. With a deep focus on promoting plant growth and resilience, ID 8-d3 functions through the modulation of key plant physiological processes. Its mode of action involves enhancing nutrient uptake, stimulating root development, and bolstering stress resilience, which is mediated by biochemical pathways that synergize with the plant’s inherent metabolic processes.</p>

<p>Repotrectinib is an inhibitor of the enzyme c-Met, which is a receptor tyrosine kinase that is involved in various cellular processes. It has been shown to have potent antitumor activity against many solid tumor cell lines and murine xenografts. Repotrectinib inhibits cancer cells by binding to the c-Met receptor and preventing it from initiating downstream signaling pathways. The drug also has a low expression in normal tissues, which limits its toxicity. Repotrectinib's mechanism of action is through inhibition of the protein secretase, which prevents the conversion of pro-caspase-1 into active caspase-1. Caspase-1 has been shown to be essential for apoptosis induction in cancer cells.</p>

<p>BW373U86 dihydrobromide is a peptide that inhibits the interaction of the receptor for epidermal growth factor with its ligands. It can be used to study the function of epidermal growth factor in cells, and as a research tool for studying protein interactions.</p>

<p>Mocravimod is a drug that belongs to the class of immunosuppressants. It is an oral, small molecule drug that inhibits sphingosine kinase and has been shown to be safe for long-term use. Mocravimod has been studied in clinical trials for inflammatory bowel disease, alopecia areata, and Crohn’s disease. The drug has also been tested in early clinical trials for cancer and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. In animal models, mocavimod has shown activity against cancers such as breast cancer, prostate cancer, colon cancer, leukemia and lymphoma.</p>

<p>Adavivint is a genetically engineered human TNF-α protein. It is a recombinant human tumor necrosis factor alpha (TNF-α) that has been modified to be less immunogenic. Adavivint is not active in the absence of other growth factors and cytokines, but can activate cells in vitro to produce proinflammatory cytokines such as IL-1β, IL-6, IL-8, and IL-12. This protein also activates cell factor and other signaling pathways that lead to the release of intracellular stores of inflammatory molecules. The effective dose for Adavivint is still being determined in clinical trials.</p>

<p>GNE-987 is a potent anticancer drug that has been developed for the treatment of various types of tumors. It is an analog of kinase inhibitors and works by inhibiting specific kinases that are involved in cancer cell growth and survival. GNE-987 induces apoptosis (programmed cell death) in cancer cells, thereby preventing their proliferation. This drug has been shown to be effective against different types of human cancer cell lines, including Chinese hamster ovary cells. GNE-987 has also demonstrated activity against urinary tract tumors in preclinical studies. As a promising medicinal compound, GNE-987 holds great potential for the development of new cancer therapies.</p>

<p>N-Methoxysuccinyl-Ala-Ala-Pro-Met p-nitroanilide is a synthetic chromogenic substrate, which is typically utilized in biochemical assays to assess protease activity, particularly that of elastase-like enzymes. The product is derived from chemical synthesis in the laboratory, featuring a specific peptide sequence conjugated to the p-nitroanilide group.</p>

<p>Tauroursodeoxycholate dihydrate is a monoclonal antibody that binds to the bile acid receptor TGR5, which is expressed in the intestines. The antibody can be activated by acetylation of its phenylalanine side chains and then bind to cancer cells in culture. Activated tauroursodeoxycholate can have anti-cancer effects, such as inhibition of cell proliferation and induction of apoptosis. Bile acids are also known to inhibit tumor growth and induce apoptosis in animal models of cancer.</p>

<p>6-[[(3S,4R)-3-Hydroxy-6-(3-hydroxyphenyl)sulfonyl-2,2,3-trimethyl-4H-chromen-4-yl]oxy]-2-methylpyridazin-3-one is a drug that is metabolized through glucuronidation. It has been shown to be water soluble and stable in the presence of sebaceous glands and follicles. The drug is transported by glycocholate and stabilizes the surface of the skin by binding to its lipids. 6-[(3S,4R)-3-Hydroxy -6-(3hydroxyphenyl)sulfonyl -2,2, 3 trimethyl 4H chromen 4 yl]oxy - 2 methylpyridazin - 3 one also binds to the dermis. This drug interacts with other drugs that have a similar chemical structure (i.e</p>

<p>Aldosterone-2,2,4,6,6,21,21-d7 is a radioactive ligand that binds to the mineralocorticoid receptor. This receptor is a member of the nuclear hormone receptors and is involved in regulating electrolyte balances in the body. Aldosterone-2,2,4,6,6,21,21-d7 binds to the receptor with high affinity and specificity. The binding site for this ligand has been mapped to amino acids 12-14 of the DNA sequence of the human mineralocorticoid receptor.</p>

<p>S-Acebutolol-d7 is a medicinal compound that has shown promising results in the treatment of cancer. It is an analog of Acebutolol, a beta-blocker that is commonly used to treat hypertension and arrhythmias. S-Acebutolol-d7 has been found to be an effective inhibitor of protein kinases, which are enzymes that play a key role in the regulation of cell growth and division. This compound induces apoptosis (programmed cell death) in cancer cells and has been shown to inhibit tumor growth in human cancer cell lines. Additionally, S-Acebutolol-d7 has demonstrated anticancer activity by blocking the cell cycle progression and suppressing the activity of inhibitors such as Chinese hamster ovary cells. This compound can be detected in urine samples and may have potential as a novel therapeutic agent for cancer treatment.</p>

<p>Please enquire for more information about Cis-asenapine including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>Peptide H-GLIQLVEGV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice.</p>

<p>CBL0137 hydrochloride is a small molecule anti-cancer agent, which is a synthetic compound derived from curaxins. It acts as an inhibitor of chromatin remodeling. The source of this compound consists of artificial synthesis designed to target molecular pathways involved in cancer cell survival.</p>

<p>Please enquire for more information about Methyl octanoate-d15 including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>Peptide H-STEPPYSQKRYEE-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice.</p>

<p>Human epidermal growth factor receptor (HER2) inhibitor</p>

<p>GSK-3 Inhibitor X is a synthetic compound that binds to glycogen synthase kinase-3 and prevents it from phosphorylating β-catenin. GSK-3 Inhibitor X has been shown to have proapoptotic effects in vitro on herpes simplex virus, cellular cancer cells, and cancer cells derived from human tumors. This compound also has antiepileptic effects in vivo, as well as an all-trans retinoic acid (ATRA)-like effect on the central nervous system. GSK-3 Inhibitor X has been shown to inhibit locomotor activity in vivo through its ability to bind to DNA, which may be related to its anti-epileptic properties.</p>

<p>Please enquire for more information about Benzthiazide-d7 including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>Briciclib disodium is a prodrug that is administered in the form of a tablet. It is used as an antineoplastic agent to treat cancer. Briciclib disodium is an analog of benzyl bromide, which is a diagnostic agent and has been used in the past to study translation and profiles. This drug can be detected in body fluids such as urine, serum, or plasma. Briciclib disodium has been shown to have potential anti-neoplastic properties and can be used for the treatment of cavity or cancer.</p>

<p>4-Pentadecylbenzylphosphonic acid is a cell permeant inhibitor of the antibody response, which can be used as a research tool for studying the function of antibodies. It can also be used to study the effects of peptides on receptor-mediated signal transduction pathways. 4-Pentadecylbenzylphosphonic acid binds to anionic phospholipids and blocks calcium ion channels by binding to their ligand binding site. This inhibits the release of neurotransmitters and slows down nerve impulses, which may help in treating pain and epilepsy.</p>

<p>(E)-Metaflumizone is an anticancer drug that induces apoptosis in human tumor cells. It is a potent inhibitor of protein kinases, including Chinese hamster ovary cell kinase and geniposide analogs. (E)-Metaflumizone has been shown to inhibit the growth of cancer cells by blocking the activity of key enzymes involved in cell division and proliferation. This drug also inhibits the activity of protein kinases, which play a crucial role in cancer development and progression. In addition, (E)-Metaflumizone has been found to be effective against a wide range of cancer types, making it a promising candidate for further clinical development.</p>

<p>Eicosyl ferulate is a research tool that binds to a receptor and activates the cell. It is used in Cell Biology and Pharmacology as an activator or ligand to study the function of ion channels, receptors, and other cell-signaling proteins. Eicosyl ferulate has been shown to be an inhibitor of protein interactions with peptides and other macromolecules. This drug also has high purity with a CAS number of 133882-79-8.</p>

<p>Please enquire for more information about 4-Methyl-N-(4-nitrophenyl)-1-piperazineacetamide including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>Please enquire for more information about Rufinamide-5-carboxamide including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>In order to to penetrate human cells, the SARS-CoV-2 coronavirus needs to dock with the host cell surface via one of its surface proteins, the so-called spike protein. This trimeric protein binds to the ACE2 receptor of human cells and enters the cell through the cell membrane. The spike glycoprotein is therefore considered to be a key target for urgently needed vaccines, antibodies and diagnostics.</p>

<p>Please enquire for more information about Benoxaprofen-13C,d3 including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>1(S),9(R)-(-)-Bicuculline methbromide is a potent inhibitor of protein kinases that has been shown to induce apoptosis in cancer cells. It is derived from the urine of Chinese strain rats and inhibits the activity of D-xylose kinase, which is involved in the metabolism of xylose. 1(S),9(R)-(-)-Bicuculline methbromide has been studied extensively for its anti-cancer properties and has shown promising results in tumor cell lines. It induces apoptosis in human cancer cells by inhibiting the activity of specific kinases that are essential for cell survival. This compound may be a potential candidate for cancer therapy due to its ability to selectively target cancer cells while sparing normal cells.</p>

<p>BMS-986235 is a research tool that has been shown to inhibit the function of ion channels. This inhibitor binds to the ligand-binding site of the receptor and blocks ATP binding, preventing activation and increasing the duration of inactivation. The high purity of BMS-986235 allows for use in pharmacological studies. BMS-986235 also inhibits peptide binding to receptors and prevents protein interactions, making it an activator as well as an inhibitor.</p>

<p>γ-Glu-Ser is a peptide that belongs to the group of activators. It is an inhibitor of ion channels and receptors, which are proteins that bind to ligands or drugs. γ-Glu-Ser has been shown to inhibit the activity of the NMDA receptor in rat brain synaptosomes. The binding site for γ-Glu-Ser was identified as a region on the NR2B subunit. This inhibition may be due to the inhibition of calcium influx through NMDA receptor channels.</p>

<p>Please enquire for more information about GX-201 including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>Please enquire for more information about 7-Methylguanine-15N5 including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>Febuxostat is a non-peptide inhibitor of xanthine oxidase (XO), an enzyme that catalyzes the conversion of xanthine and hypoxanthine to uric acid. Febuxostat is used as a treatment for chronic gout in adults who are not adequately controlled on allopurinol alone or who cannot tolerate allopurinol. Febuxostat has been shown to be effective in inhibiting the activity of human recombinant XO, both in vitro and in vivo. The compound is a competitive inhibitor of L-histidine with an IC50 of 0.3 microM at pH 7.4 and 0.1 microM at pH 6.0, which is more potent than other peptidomimetics such as febuprofen and fexofenadine, but less potent than CGP57148B and CGP37849A.<br>Febuxostat has also been shown to have</p>

<p>N-Desmethyl Rosuvastatin-d3 Sodium Salt is a stable isotope-labeled compound, which is a synthetically produced standard. It serves as an internal standard in analytical chemistry, particularly in pharmacokinetic and metabolism studies. The compound incorporates deuterium atoms, denoted by "d3," which allows researchers to distinguish it from non-labeled equivalents through mass spectrometry techniques.</p>

<p>NPI64 is an antiviral agent that has been shown to be effective against coronavirus. This drug is a nucleoside analog that inhibits viral RNA-dependent DNA polymerase. It has been shown to inhibit the replication of virulent coronaviruses in humans and animals, and can be used as a diagnostic tool for the detection of these viruses. NPI64 is not active against non-virulent viruses and there are no known treatments for zoonotic coronavirus infections. There are currently no licensed vaccines or antivirals available, but NPI64 may provide a viable treatment option for such infections.</p>

<p>Deshydroxyethoxy Ticagrelor is a metabolite that emerges as a derivative of the antiplatelet medication Ticagrelor. This compound originates from the biotransformation processes in the human body, where Ticagrelor undergoes metabolic conversion. As a metabolite, Deshydroxyethoxy Ticagrelor retains activity, contributing to the parent compound's overall therapeutic effect. The primary mode of action involves the reversible inhibition of the P2Y12 receptor on platelets, which plays a crucial role in the inhibition of platelet aggregation.<br><br>The applications of Deshydroxyethoxy Ticagrelor are primarily linked to the study of its pharmacokinetic and pharmacodynamic properties to understand better its contribution to Ticagrelor's efficacy and safety profile. Such insights can help refine dosing strategies and therapeutic regimens in clinical settings, enhancing antiplatelet therapy's precision, especially in managing acute coronary syndromes and preventing thrombotic vascular events. Understanding this metabolite is essential for developing next-generation antiplatelet agents and optimizing current treatment protocols.</p>

<p>Analog of the native Melan-A (26-35) decapeptide derives from the melanocyte lineage-specific protein Melan-A/MART-1, which is expressed in almost 75-100% of primary and metastatic melanomas.<br>The region 26-35 of Melan-A protein acts as an antigenic peptide that is recognized by CD8+ tumor-reactive cytolytic T lymphocytes (CTLs) for designing antigen-specific cancer vaccines1. It has been shown that CD8+ Melan-A-specific CTLs isolated from melanoma patients efficiently lyse the Melan-A-expressing HLA-A*0201+ melanoma cell line. However, CTLs preferentially recognize the Melan-A (26-35) peptide as compared with the Melan-A (27-35) peptide. Moreover, the Melan-A (26-35) A27L analog (ELAGIGILTV) has a higher binding affinity to HLA-A*0201 than the native Melan-A (26-35) peptide (EAAGIGILTV), and consequently displays more potent antigenicity and immunogenicity.<br>It has been reported that the concentration of Melan-A (26-35) A27L analog required to obtain 50% of maximal antigenic activity (EC50) is 0.01nM, whereas that of the native Melan-A (26-35) peptide is 0.25nM1. Therefore, the relative activity of Melan-A (26-35) A27L analog is 25 fold higher than that of the native Melan-A (26-35) peptide.<br>Furthermore, functional competition assay has shown that the concentration of Melan-A (26-35) A27L analog required to achieve 50% inhibition (IC50) of tumor lysis is 2nM, which is 10 fold lower than that of the native Melan-A (26-35) peptide. Regarding peptide stability in human serum, the half-lifes (t1/2) of the native Melan-A (26-35) peptide and the A27L analog are quite similar (45 and 40min, respectively) as measured by HPLC-ESI-MS, but much higher than that of the Melan-A (27-35) nonapeptide (5min).</p>

<p>VU 0365114 is a novel compound that is synthesized to act as an allosteric modulator of the acetylcholine receptor. It has been shown to have antagonistic properties at the receptor subtype. VU 0365114 has been found to be active in knockout mice, and it was able to produce effects in the ventral tegmental area and substantia nigra. The drug was also able to increase phosphatidyl fumarate levels, which may be due to its ability to inhibit fumarate reductase activity.</p>

<p>D-(-)-Amethopterin hydrate is an analog of methotrexate, a chemotherapy drug used to treat cancer. It is a potent inhibitor of dihydrofolate reductase, an enzyme involved in the synthesis of DNA, RNA and proteins. D-(-)-Amethopterin hydrate has been shown to induce apoptosis in cancer cells by inhibiting the activity of kinases that regulate cell growth and survival. This drug has also demonstrated anti-tumor activity in human cancer cell lines and Chinese hamster ovary cells. Additionally, D-(-)-Amethopterin hydrate has been found to enhance the activity of rifampicin, an antibiotic used to treat tuberculosis. Its potential as a therapeutic agent for cancer treatment makes it a promising candidate for further research and development.</p>

<p>VER-246608 is a fatty acid that inhibits aerobic glycolysis in cancer cells. It has been shown to inhibit the proliferation of lung cell lines and to induce apoptosis. VER-246608 also affects the mitochondrial membrane potential, which can lead to cell death. The pharmacokinetic properties of VER-246608 have been studied in a microenvironment model system and its effects on suppressor genes are being investigated as a prognostic factor for cancer patients.</p>

<p>18:1 PI(3,4,5)P3 is a phosphatidylinositol polyphosphate, which is a signaling lipid molecule derived from a glycerophospholipid source, commonly used in biochemical research. It is a product of the PI3K (phosphoinositide 3-kinase) pathway, where it acts as a secondary messenger involved in various cellular processes. This lipid plays a critical role in signal transduction by recruiting proteins with pleckstrin homology (PH) domains to the cell membrane, thereby modulating cell growth, proliferation, survival, and migration.</p>

<p>The compound is a research tool that can be used in the fields of cell biology, pharmacology, and biochemistry. It has been shown to inhibit ion channels and receptor ligand interactions. The CAS number is 2075629-81-9 and the purity is high. The compound is not intended for therapeutic use.</p>

<p>rac-Balanol is an inhibitor that has shown promising results in the treatment of tumors and cancer cells. It is a derivative of ranolazine, a drug used to treat angina. rac-Balanol has been found to inhibit protein kinases in Chinese hamster ovary cells and human urine. This inhibition leads to apoptosis, or programmed cell death, which can be beneficial in the treatment of cancer. Rac-Balanol has also been found to have anticancer properties when combined with other kinase inhibitors such as ranitidine.</p>

<p>Please enquire for more information about Desbenzoyl docetaxel including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>Please enquire for more information about Acetophenone-13C8 including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>N-[2-(2,6-Dimethylphenoxy)-1-methylethyl]acetamide is a human analog that has been studied for its potential anticancer properties. It is an inhibitor of kinases, which are enzymes that play a critical role in cell signaling and regulation. This compound has been shown to induce apoptosis (cell death) in Chinese hamster ovary cells and to inhibit tumor growth in medicinal studies. N-[2-(2,6-Dimethylphenoxy)-1-methylethyl]acetamide has also been found to be effective against cancer cells by inhibiting protein kinase activity, which is essential for the growth and survival of cancer cells. Additionally, it has been detected in human urine samples and may have potential as a cancer treatment option. Its unique chemical structure makes it an interesting candidate for further research into developing new anticancer therapies.</p>

<p>Bromoacetamido-dPEG®12-TFP Ester is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. Bromoacetamido-dPEG®12-TFP Ester is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.</p>

<p>Glucuronic acid is a naturally occurring sugar that plays a critical role in the body's detoxification process. It is used in the formation of glucuronides, which are conjugated compounds that aid in the elimination of toxins and other harmful substances from the body. Glucuronic acid has been found to have anticancer properties, as it induces apoptosis (programmed cell death) in cancer cells. It also inhibits protein kinase activity, which is involved in regulating cell growth and division. Chinese medicinal herbs containing glucuronic acid analogs have been used traditionally to treat various types of tumors. Additionally, glucuronic acid has been shown to be an inhibitor of the cell cycle, making it a potential target for cancer therapy. This compound can be found in urine and is often used as a biomarker for various diseases and conditions.</p>

<p>RU 58841 is a non-steroidal anti-androgen, which is a chemical compound sourced through synthetic processes in pharmaceutical laboratories. It functions by selectively binding to androgen receptors in the hair follicles, thereby inhibiting the action of androgens such as dihydrotestosterone (DHT). This mode of action prevents DHT from activating the receptor, which is a critical factor in the miniaturization of hair follicles.</p>